作者
Michael P Menden, Dennis Wang, Mike J Mason, Bence Szalai, Krishna C Bulusu, Yuanfang Guan, Thomas Yu, Jaewoo Kang, Minji Jeon, Russ Wolfinger, Tin Nguyen, Mikhail Zaslavskiy, AstraZeneca-Sanger Drug Combination DREAM Consortium, In Sock Jang, Zara Ghazoui, Mehmet Eren Ahsen, Robert Vogel, Elias Chaibub Neto, Thea Norman, Eric KY Tang, Mathew J Garnett, Giovanni Y Di Veroli, Stephen Fawell, Gustavo Stolovitzky, Justin Guinney, Jonathan R Dry, Julio Saez-Rodriguez
发表日期
2019/6/17
期刊
Nature communications
卷号
10
期号
1
页码范围
1-17
出版商
Nature Publishing Group
简介
The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca’s large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all …
学术搜索中的文章
MP Menden, D Wang, MJ Mason, B Szalai, KC Bulusu… - Nature communications, 2019
